Charta Health Raises $55M to Expand AI Chart Review Across Payers

By Amara Osei

Charta Health announced a $55 million Series B on November 10, 2026, led by Insight Partners, to expand its AI chart-review technology. The financing also drew QuantumLight and returning investors Madrona, Bain Capital Ventures and South Park Commons.

Charta Health will direct the capital toward further AI development for provider customers and entry into additional specialties. The company’s stated goal is establishing one trusted interpretation of a chart before billing, according to its announcement.

Alongside the financing, Charta Health broadened Charta for Payers with a suite initially aimed at Medicare Advantage and Affordable Care Act Marketplace plans. Charta Health said it designed the suite with one of the nation’s largest health insurers, which it did not name.

Why did Insight Partners back Charta Health?

Insight Partners co-founder and managing director Jeff Horing pointed to Charta Health’s pairing of AI and customer-specific coding expertise across providers and payers. “As payers and providers both adopt AI, we believe the opportunity lies in getting the underlying record, or the ‘ground truth,’ right before a claim is submitted,” Horing said.

What does provider software do before billing?

Charta Health says its provider software reviews every chart before billing against coding guidelines, payer rules and each customer’s clinical protocols. Charta Health says findings appear for human approval inside the electronic health record, leaving staff to validate the issues flagged by the system.

Charta Health says its software applies large language models to free-text notes, scanned orders, laboratory results and images. The company says the system establishes what care was delivered and whether documentation supports billing. Charta Health says that review moves accuracy checks ahead of the denials and appeals that can follow a claim.

Charta Health says compliance and medical leaders can examine documentation deficiencies, error patterns and provider performance across patient encounters. Charta Health identified American Family Care, Grow Therapy and Pediatric Associates Family of Companies among healthcare enterprises using the technology. The company reports consistent double-digit reductions in denial rates for fee-for-service billing.

How does Charta for Payers work?

Charta Health’s payer products look for documented conditions that were not coded and coded diagnoses that lack support in the chart. Charta Health says the suite spans six product areas:

• Retrospective diagnosis coding.
• Automated second-pass coding.
• Smart coding workspace.
• Prospective risk-adjustment intelligence.
• Diagnosis validation and audit workflow.
• Quality care-gap detection.

Charta Health says the payer platform extracts structured clinical and encounter intelligence from records that plans already retrieve. The company says the evidence can support retrospective coding, second-pass quality assurance, audit work and prospective workflows.

Charta Health says its automated second-pass product applies AI to 100% of coded charts. According to Charta Health, the smart coding workspace presents supporting evidence, citations, and additions and deletions for validation in one review.

What happens in retrospective risk adjustment?

Charta Health says that, in retrospective risk adjustment, AI presents clinical evidence to human coders, who apply customer-specific guidelines. The company says those coders validate additional diagnoses and flag unsupported codes for deletion.

Smart Scan pre-screens the chart population to identify records with enough potential value to warrant full review, Charta Health said. Charta Health advertises 98% accuracy for diagnosis coding in this workflow, based on the combination of AI evidence recall and human validation.

How does this round fit Charta Health’s funding history?

Charta Health announced its $22 million Series A on July 22, 2025, led by Bain Capital Ventures. Madrona, SV Angel, Refract Ventures and South Park Commons participated in that earlier financing.

Charta Health said its total funding exceeded $30 million at the time of the Series A announcement. The July 2025 announcement focused on automating provider chart review; the new financing pairs continued provider development with a broader payer product rollout.

What must Charta Health prove next?

Charta Health frames a shared chart record as the central test of its model. The company says the same evidence can help providers submit better-supported claims and payers identify unsupported diagnoses. Charta Health’s next commercial test is whether it can make the review dependable enough for both sides while humans remain responsible for coding decisions.